Journals / Namık Kemal Tıp Dergisi / 2020 / Cilt: 8 - Sayı: 3

Prognostic Factors in Operated Early Stage Lung Cancer Patients- Retrospective Single Center Data

OPERE ERKEN EVRE AKCİĞER KANSERİ HASTALARINDA PROGNOSTİK FAKTÖRLER RETROSPEKTİF TEK MERKEZ SONUÇLARI

Pages
376–382
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median disease free survival (DFS) and overall survival (OS) were 76 months (%95CI:32.1-110.0) and 87 months (95%CI:59.8-114.1). ).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers.
📊
Key Findings & Data:In this study, we retrospectively evaluated the prognostic factors and outcomes of operated NSCLC cases.
💡
Conclusion & Impact:Median disease free survival (DFS) and overall survival (OS) were 76 months (%95CI:32.1-110.0) and 87 months (95%CI:59.8-114.1). ).
🔬Design:Research Article
📍Scope:2006-2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. Although curative treatment is surgery in the early stages, disease relapse is common. In this study, we retrospectively evaluated the prognostic factors and outcomes of operated NSCLC cases. Materials and Methods: Retrospective analysis of data from 166 patients with early stage NSCLC who presented after surgery and treated and followed in our clinic between 2006-2018 was performed. Histopathologic features and clinical findings were investigated as prognostic factors.The findings were analyzed using SPSS. Results: At the time of diagnosis, median age was 61 (39-82) and 84% of the patients were male. Most common pathologic subtype was adenocarcinoma. Median disease free survival (DFS) and overall survival (OS) were 76 months (%95CI:32.1-110.0) and 87 months (95%CI:59.8-114.1). ). In multivariate analysis, presence of vascular invasion was found to be independent prognostic factors for both DFS and OS (HR:2.5 and 2.3, respectively). Adenocarcinoma solid pattern was only associated with worse disease-free survival (HR: 1.7). Conclusion: In our study, we showed that the presence of vascular invasion and solid-type adenocarcinoma is associated with poor survival.

Özet

Amaç: Küçük hücreli dışı akciğer kanseri (KHDAK) tüm akciğer kanserlerinin %85’ini oluşturmaktadır. Erken evre hastalıkta cerrahi ile küratif tedavi hedeflense de nüks sık görülmektedir. Bu çalışmada merkezimizde opere olan erken evre KHDAK tanılı hastaların sonuçlarını ve prognoza etkili faktörleri retrospektif olarak değerlendirdik. Materyal ve Metot: 2006-2018 yılları arasında kliniğimize başvuran 166 opere erken evre KHDAK hastasının dosyası retrospektif olarak değerlendirildi. Bulgular SPSS kullanılarak analiz edildi. Histopatolojik ve klinik özelliklerin için prognostik önemi araştırıldı. Bulgular: Hastalarımızın %84’ü erkekti. Medyan tanı yaşı 61 (39-82)’di. En sık görülen patolojik alt tip adenokarsinomdu. Medyan hastalıksız sağkalım (HSK) ve genel sağkalım (GSK) 76 ay (%95CI:32.1-110.0) ve 87 aydı (95%CI:59.8-114.1). Çok değişkenli analizde vaskuler invazyon varlığı daha kötü HSK ve GSK için bağımsız prognostik faktördü (HR: 2,5 ve 2.3). Adenokarsinom solid patern ise sadece daha kötü HSK ile ilişkiliydi (HR:1.7).. Sonuç: Çalışmamızda vaskuler invazyon varlığının ve solid tip adenokarsinomun kötü sağ kalım ile ilişkili olduğunu gösterdik.

🔖

Cite This Article

ALAN, Ö., ERCELEP, Ö., TELLİ, T. A., TANRIKULU, E. Ş., HASANOV, R., BASOGLU, T., ÖZTÜRK, M. A., KAYA, S. Ş., AKGUL, N. B., LAÇİN, T., BOZKURTLAR, E. B., DANE, F., YUMUK, P. F. (2020). Prognostic Factors in Operated Early Stage Lung Cancer Patients- Retrospective Single Center Data. Namık Kemal Tıp Dergisi, Cilt: 8 - Sayı: 3, 376–382. https://ajindex.com/articles/288958

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70:7
  2. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016;11(10):1653-71
  3. Didkowska J, Wojciechowska U, Mańczuk M, Łobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016;4(8):150. doi:10.21037/atm.2016.03.11 4. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours [published correction appears in J Thorac Oncol. 2007 Oct;2(10):985]. J Thorac Oncol. 2007;2(8):706–14
  4. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2002; 123:280
  5. Yi E, Bae MK, Cho S, Chung JH, Jheon S, Kim K. Pathological prognostic factors of recurrence in early stage lung adenocarcinoma. ANZ J Surg.2018;88(4):327–31
  6. Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer. 2009;115(4):851–8
  7. Hsu CP, Hsia JY, Chang GC, et al. Surgical-pathologic factors affect long-term outcomes in stage IB (pT2 N0 M0) non-small cell lung cancer: a heterogeneous disease. J ThoracCardiovasc Surg. 2009;138(2):426–33
  8. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117(2):294–9
  9. Yousem SA, Beasley MB. Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. Arch Pathol Lab Med. 2007;131(7):1027–32
  10. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 2015; 10:1243
  11. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-64
  12. Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study